



Revised Prior Authorization Policy for Pharmacy Providers

February 6, 2022

Effective immediately and retroactive to January 1, 2022, Medi-Cal Rx has implemented a revised prior authorization (PA) policy.

Note: Pharmacies should resubmit claims that were previously denied with Reject Code 75, if they have not done so yet.

Medi-Cal Rx is temporarily adjusting some PA requirements, as noted below, to optimize access to patient care and therapies during this transition period.

Please continue to follow Point-of-Sale (POS) messages.

Note: Pharmacies should not prospectively submit PAs **at this time** if the claim is paying.

Reject Code 75 Edit

Effective immediately, the PA requirement will be removed temporarily for some drugs, except for the following:

- Opioid analgesics
- Ataractics – Tranquillizers (including antipsychotics and benzodiazepines)
- Certain excluded products for children under the age of 21

PAs may still be required for other reject codes such as quantity limits and Reject Code 76. The existing Price Override Policy remains in place.

Note: The Contract Drugs List (CDL), Drug Lookup Tool (DLT), and ePrescribing file may not reflect this temporary change.